Drugs often exert their effects by binding to targets within cells to alter subsequent actions of the target in an effort to treat disease. Below is the Therapeutic Target Dashboard summarizing evidence for treatments of HHV-8-negative/idiopathic multicentric Castleman disease (iMCD) that have been published in scientific literature. We were inspired by our colleagues at the Chordoma Foundation (https://www.chordomafoundation.org/targets/). While only two clinical trials have been performed on drugs specifically to treat idiopathic multicentric Castleman disease (iMCD), the evidence compiled below suggests that additional targets including different proteins and signaling pathways can serve as therapeutic targets for treatment of iMCD. 

Treatment Target  Treatment Molecular Evidence (Rationale) Case Reports (Potential/Tested Therapies) Clinical Trials for iMCD
IL-6 Siltuximab yes yes yes, approved by FDA in 2014
  Tocilizumab yes yes yes, approved by Japanese regulatory agency in 2005
IL-1 Anakinra yes yes  
mTOR Sirolimus yes yes  
VEGF Sirolimus yes yes  
Proteasome Bortezomib yes yes  
Plasma cells Bortezomib yes yes  
NF-kB Bortezomib yes yes  
  Corticosteroids yes yes  
B-cells Rituximab yes yes  
T-cells Cyclosporin yes yes  
Calcineurin Cyclosporin yes yes  
NFAT  None yes    
Nonspecific cytotoxic immuno-depletion CHOP yes yes  
  CVP yes yes  
  Cyclophosphamide yes yes  
Non-specific immune activation Corticosteroids yes yes  
  IVIg yes yes  

This therapeutic target database was last updated 4/2017.